Key facts
- Precision oncology startup 4baseCare raised Rs 128 crore in a funding round.
- The funding was led by growX Ventures and Infosys.
- The capital will be used for global expansion of its genomics labs and AI-led oncology platform, OncoTwin.
- 4baseCare aims to address gaps in population-relevant genomic data for under-represented populations.
- The company plans to expand into 8-10 new countries within 12-18 months.
- 4baseCare currently operates four labs in India and plans to increase monthly testing volume to 8,000-10,000.
Precision oncology startup 4baseCare has secured Rs 128 crore in funding, with a Rs 38 crore top-up round led by growX Ventures and Infosys, alongside existing investors. The company previously raised Rs 90 crore from investors including Ashish Kacholia and Lashit Sanghvi.
The fresh capital is earmarked for expanding its genomics laboratory network globally and scaling its AI-led oncology platform, OncoTwin. 4baseCare aims to make precision oncology more inclusive by developing solutions for under-represented populations in India, the Middle East, Southeast Asia, and Latin America, addressing the current concentration of genomic data in the US and Europe.
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare develops genomics-driven cancer diagnostics and AI-powered clinical decision support tools. The company operates labs in India, Dubai, Nepal, and the Philippines, with plans to enter 8-10 additional countries within the next 12-18 months. It is also decentralizing genomic testing infrastructure in India through partnerships with hospitals like Max Healthcare, AIIMS Jammu, and Shankara Hospital to improve turnaround times and accessibility.
Currently, 4baseCare operates four labs in India, conducting approximately 1,500 genomic tests monthly. With its expansion plans, the company anticipates scaling this to 8,000-10,000 tests per month. The startup has focused on lowering costs, with some offerings priced at one-fourth of competing solutions, and aims for genomic testing to be included in public healthcare schemes.
Globally, precision oncology is a rapidly growing field, but most datasets are dominated by Caucasian populations. 4baseCare's OncoTwin platform uses multimodal data to create digital twins of cancer patients, matching them with similar treatment journeys and outcomes. Infosys's investment is strategic, recognizing 4baseCare's AI and healthcare data capabilities. The company, which has been revenue positive for five years, currently generates around Rs 40 crore annually and projects crossing Rs 100 crore in revenue within 18 months.